Therapeutic management of posttransplant diabetes mellitus

Transplantation Reviews

Volumn 22, Issue 2, 2008, Pages 116-124

  Mannon, Roslyn B ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; PRECOS; RAPAMYCIN; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; STARLIZ; SULFONYLUREA; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BLOATING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG APPROVAL; DRUG CHOICE; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; KIDNEY DYSFUNCTION; LACTIC ACIDOSIS; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORGAN TRANSPLANTATION; OUTCOMES RESEARCH; RISK MANAGEMENT; SCREENING TEST; SIDE EFFECT; WEIGHT GAIN;

AFRICAN AMERICANS; AGE FACTORS; DIABETES MELLITUS; HEPATITIS C; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; OBESITY; ORGAN TRANSPLANTATION; RISK FACTORS; TACROLIMUS;

EID: 40649112628     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2007.12.003     Document Type: Article

References (80)

1. R.S. Woodward M.A. Schnitzler J. Baty Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients Am J Transplant 3 2003 590 598
2. B.L. Kasiske J.J. Snyder D. Gilbertson A.J. Matas Diabetes mellitus after kidney transplantation in the United States Am J Transplant 3 2003 178 185
3. R.D. Bloom V. Rao F. Weng R.A. Grossman D. Cohen K.C. Mange Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus J Am Soc Nephrol 13 2002 1374 1380
4. J. Davidson A. Wilkinson J. Dantal New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003 Transplantation 75 2003 S3 S24
5. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Diabetes Care 26 2003 5S 20S
6. E. Sulanc J.T. Lane S.E. Puumala G.C. Groggel L.E. Wrenshall R.B. Stevens New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines Transplantation 80 2005 945 952
7. M.R. Weir J.C. Fink Risk for posttransplant diabetes mellitus with current immunosuppressive medications Am J Kidney Dis 34 1999 1 13
8. S.M. Grundy Metabolic syndrome: a multiplex cardiovascular risk factor J Clin Endocrinol Metab 92 2007 399 404
9. 1c as the sole measure of glycemic control Clin Diabetes 22 2004 141 143
10. D.M. Nathan D.E. Singer K. Hurxthal J.D. Goodson The clinical information value of the glycosylated hemoglobin assay N Engl J Med 310 1984 341 346
11. H.E. Lebovitz M.M. Austin L. Blonde ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations Endocr Pract 12 Suppl 1 2006 6 12
12. American Diabetes Association Diagnosis and classification of diabetes mellitus Diabetes Care 30 2007 S42 S47
13. S. Genuth Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes Endocr Pract 12 Suppl 1 2006 34 41
14. W.C. Knowler E. Barrett-Connor S.E. Fowler Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
15. D.G. Marrero Changing patient behavior Endocr Pract 12 Suppl 1 2006 118 120
16. K. Kulkarni Diets do not fail: the success of medical nutrition therapy in patients with diabetes Endocr Pract 12 Suppl 1 2006 121 123
17. M.R. First D.A. Gerber S. Hariharan D.B. Kaufman R. Shapiro Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management Transplantation 73 2002 379 386
18. F. Vincenti S. Friman E. Scheuermann Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus Am J Transplant 7 2007 1506 1514
19. T. Gonwa R. Mendez H.C. Yang S. Weinstein S. Jensik S. Steinberg Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months Transplantation 75 2003 1213 1220
20. J.J. Augustine K.A. Bodziak D.E. Hricik Use of sirolimus in solid organ transplantation Drugs 67 2007 369 391
21. J.C. Lopez-Talavera A. Garcia-Ocana I. Sipula K.K. Takane I. Cozar-Castellano A.F. Stewart Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation Endocrinology 145 2004 467 474
22. J.P. Fryer D.K. Granger J.R. Leventhal K. Gillingham J.S. Najarian A.J. Matas Steroid-related complications in the cyclosporine era Clin Transplant 8 1994 224 229
23. L.W. Miller Cardiovascular toxicities of immunosuppressive agents Am J Transplant 2 2002 807 818
24. M. Giessing T.F. Fuller M. Tuellmann T. Slowinski K. Budde L. Liefeldt Steroid- and calcineurin inhibitor free immunosuppression in kidney transplantation: state of the art and future developments World J Urol 25 2007 325 332
25. J.J. Jaber P.J. Feustel O. Elbahloul A.D. Conti M.H. Gallichio D.J. Conti Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol Clin Transplant 21 2007 101 109
26. J. Pascual J.P. van Hooff K. Salmela P. Lang P. Rigotti K. Budde Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant Transplantation 82 2006 55 61
27. A. Haririan D.H. Sillix K. Morawski Short-term experience with early steroid withdrawal in African-American renal transplant recipients Am J Transplant 6 2006 2396 2402
28. A.J. Scheen Drug interactions of clinical importance with antihyperglycaemic agents: an update Drug Saf 28 2005 601 631
29. Y. Shu S.A. Sheardown C. Brown Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action J Clin Invest 117 2007 1422 1431
30. M.S. Wu P. Johnston W.H. Sheu Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients Diabetes Care 13 1990 1 8
31. M.O. Goodarzi M. Bryer-Ash Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents Diabetes Obes Metab 7 2005 654 665
32. C.J. Bailey R.C. Turner Metformin N Engl J Med 334 1996 574 579
33. J.D. Lalau C. Mourlhon A. Bergeret C. Lacroix Consequences of metformin intoxication Diabetes Care 21 1998 2036 2037
34. C.R. Sirtori G. Franceschini M. Galli-Kienle Disposition of metformin ( N , N -dimethylbiguanide) in man Clin Pharmacol Ther 24 1978 683 693
35. L. Aguilar-Bryan C.G. Nichols S.W. Wechsler Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion Science 268 1995 423 426
36. S. Del Prato N. Pulizzi The place of sulfonylureas in the therapy for type 2 diabetes mellitus Metabolism 55 2006 S20 S27
37. J.B. Green M.N. Feinglos Are sulfonylureas passé? Curr Diab Rep 6 2006 373 377
38. S.E. Kahn S.M. Haffner M.A. Heise Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2006 2427 2443
39. J. Fuhlendorff P. Rorsman H. Kofod Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes Diabetes 47 1998 345 351
40. S. Schumacher I. Abbasi D. Weise Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment Eur J Clin Pharmacol 57 2001 147 152
41. M.H. Voytovich C. Haukereid J. Hjelmesaeth A. Hartmann A. Lovik T. Jenssen Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients Clin Transplant 21 2007 246 251
42. T. Turk F. Pietruck S. Dolff Repaglinide in the management of new-onset diabetes mellitus after renal transplantation Am J Transplant 6 2006 842 846
43. P. Gervois J.C. Fruchart B. Staels Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator–activated receptors Nat Clin Pract Endocrinol Metab 3 2007 145 156
44. R.W. Nesto D. Bell R.O. Bonow Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association Diabetes Care 27 2004 256 263
45. D. Baldwin Jr. K.E. Duffin Rosiglitazone treatment of diabetes mellitus after solid organ transplantation Transplantation 77 2004 1009 1014
46. G. Villanueva D. Baldwin Rosiglitazone therapy of posttransplant diabetes mellitus Transplantation 80 2005 1402 1405
47. S.E. Nissen K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
48. P.D. Home S.J. Pocock H. Beck-Nielsen Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis N Engl J Med 357 2007 28 38
49. B.M. Psaty C.D. Furberg The record on rosiglitazone and the risk of myocardial infarction N Engl J Med 357 2007 67 69
50. M.F. Saad S. Greco K. Osei Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm Diabetes Care 27 2004 1324 1329
51. B.K. Skrumsager K.K. Nielsen M. Muller G. Pabst P.G. Drake B. Edsberg Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes J Clin Pharmacol 43 2003 1244 1256
52. R.R. Koski Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus Diabetes Educ 32 2006 869 876
53. J.L. Chiasson R.G. Josse R. Gomis M. Hanefeld A. Karasik M. Laakso Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial JAMA 290 2003 486 494
54. M. Salehi D.A. D'Alessio New therapies for type 2 diabetes based on glucagon-like peptide 1 Cleve Clin J Med 73 2006 382 389
55. J.F. Gautier S. Fetita E. Sobngwi C. Salaun-Martin Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes Diabetes Metab 31 2005 233 242
56. K.B. Degn C.B. Juhl J. Sturis One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes Diabetes 53 2004 1187 1194
57. S. Madsbad O. Schmitz J. Ranstam G. Jakobsen D.R. Matthews Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial Diabetes Care 27 2004 1335 1342
58. J.B. Buse R.R. Henry J. Han D.D. Kim M.S. Fineman A.D. Baron Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 27 2004 2628 2635
59. R.A. Defronzo R.E. Ratner J. Han D.D. Kim M.S. Fineman A.D. Baron Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 28 2005 1092 1100
60. D.M. Kendall M.C. Riddle J. Rosenstock Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 28 2005 1083 1091
61. J.Q. Purnell C. Weyer Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity Treat Endocrinol 2 2003 33 47
62. D.F. Rodriquez M. Navarro E. Alvarez Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats Metabolism 49 2000 709 717
63. A. Flint A. Raben A. Astrup J.J. Holst Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans J Clin Invest 101 1998 515 520
64. K.A. Ghofaili M. Fung Z. Ao Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes Transplantation 83 2007 24 28
65. N. Ogawa J.F. List J.F. Habener T. Maki Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4 Diabetes 53 2004 1700 1705
66. A. Sharma A. Sorenby A. Wernerson S. Efendic M. Kumagai-Braesch A. Tibell Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes Diabetologia 49 2006 1247 1253
67. D. Kim L. MacConell D. Zhuang Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes Diabetes Care 30 2007 1487 1493
68. R.E. Amori J. Lau A.G. Pittas Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 298 2007 194 206
69. G.A. Herman C. Stevens K. Van Dyck Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses Clin Pharmacol Ther 78 2005 675 688
70. J.A. Pospisilik J. Martin T. Doty Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats Diabetes 52 2003 741 750
71. P. Aschner M.S. Kipnes J.K. Lunceford M. Sanchez C. Mickel D.E. Williams-Herman Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 29 2006 2632 2637
72. I. Raz M. Hanefeld L. Xu C. Caria D. Williams-Herman H. Khatami Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus Diabetologia 49 2006 2564 2571
73. P.L. Brubaker Incretin-based therapies: mimetics versus protease inhibitors Trends Endocrinol Metab 18 2007 240 245
74. R.C. Turner C.A. Cull V. Frighi R.R. Holman Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA 281 1999 2005 2012
75. S. Mudaliar S.V. Edelman Insulin therapy in type 2 diabetes Endocrinol Metab Clin North Am 30 2001 935 982
76. I.B. Hirsch Insulin analogues N Engl J Med 352 2005 174 183
77. W.T. Cefalu Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents Clin Pharmacol Ther 81 2007 636 649
78. Insulin administration Diabetes Care 27 2004 S106 S107
79. V.P. Guntur R. Dhand Inhaled insulin: extending the horizons of inhalation therapy Respir Care 52 2007 911 922
80. E. Standl M. Fuchtenbusch The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in type II diabetes mellitus Diabetologia 46 Suppl 1 2003 M30 M36